用FISH法检测胃癌组织HER-2基因扩增的临床意义及其与预后的关系

Use of FISH in detection of HER-2 gene and its clinical significance in human gastric carcinoma

目的探讨胃癌组织中HER-2基因的扩增与胃癌患者临床病理特征及预后之间的关系。方法采用荧光原位杂交技术(FISH)检测119例胃癌组织中的HER-2基因扩增状态,分析HER-2基因与胃癌临床病理参数及预后的相关性。结果 119例胃癌组织中,HER-2阳性19例(16%),阴性100例(84%)。HER-2基因扩增与肿瘤部位、lauren分型、脉管浸润、淋巴结转移有关(P<0.05),与患者性别、年龄、肿瘤大小、肿瘤分化程度、肿瘤浸润深度无关(P>0.05)。HER-2阳性和阴性患者的总体生存率差异不显著(P>0.05)。结论胃癌HER-2基因与患者的部分临床病理特征有关,可作为判断胃癌生物学行为的重要指标,但HER-2基因的扩增不能作为胃癌的独立预后指标,其与预后的关系还需进一步研究。

Objective To detect the amplificated proportion of the HER-2 gene and to explore the association of the HER-2 gene amplification with the clinical and pathological meaning in gastric cancer. Methods One hundred and nineteen cases of gastric cancer were detected by fluorescence in situ hybridization （ FISH ） , to analyze the correlation of the HER-2 gene amplification and clinicopathologic parameters in gastric cancer. Rusults The amplification of HER-2 gene existed in 19 cases （15.97%）, while 100 cases had no HER-2 gene amplification （84. 03% ）. HER-2 gene amplification was associated with site of tumor, Lauren classification, vessel infiltrating and lymph node metastasis （P 〈 0. 05）. No association was found with sex, age, tumor size and differentiation and the depth of invasion. The overall survival in HER-2-positive and negative patients were not significant difference （P 〉 0. 05 ）. Conclucion The amplification of HER-2 gene is significantly related with the clinical and pathological characters, and it can be used as the index of biology behaviors in gastric carcinoma.